BioCentury
ARTICLE | Clinical News

LineaRx produces CAR T cells via non-viral, plasmid-free platform

April 19, 2019 12:43 AM UTC

LineaRx said its non-viral, plasmid-free manufacturing platform was able to induce anti-CD19 CAR expression in human T cells. The platform uses PCR manufacturing to create a linear DNA amplicon encoding anti-CD19, which is then electroporated into T cells ex vivo.

LineaRx is using the platform to develop and produce expression vectors for CAR T therapies, including its non-viral, plasmid-free anti-CD19 CAR T therapy LinCART19...

BCIQ Company Profiles

Applied DNA Sciences Inc.